The pandemic has had a huge impact on consumer behavior, which has helped transform the housing market. Opendoor Technologies (NASDAQ:OPEN) is expanding and moving towards acquiring more properties. OPEN stock has had a wild ride over the past year. The stock was trading for $11.57 on July 8, 2020, and hit an all time high
admin
NIO (NYSE:NIO) stock has dropped roughly 14% over the past week, as fears related to a broader economic slowdown impede bullish sentiment on NIO stock. Just look around: pent-up consumer demand is tapering off and Covid-19 variants are causing sporadic lockdowns globally. Source: Sundry Photography / Shutterstock.com But look at this dip as a favorable
SoFi (NASDAQ:SOFI) hasn’t had a great month. Over the past 30 days, SOFI stock has tumbled about 30%. But that’s no reason to cower. In fact, we think SoFi’s dip is a great opportunity to buy into SOFI stock on the cheap. Source: rafapress / Shutterstock.com We attribute the selloff to a flurry of fintech
Big data analytics company Palantir Technologies (NYSE:PLTR) might be known for providing counter-terrorism-focused intelligence to U.S. government agencies. Yet, there are other angles for PLTR stock traders to consider. Source: Ascannio / Shutterstock.com For one thing, Palantir doesn’t exclusively work with the government. Indeed, the company has established business ties with a number of private enterprises.
Short-squeeze stocks are making headlines as the collective action of the Reddit community provides positive momentum for their share prices. However, many dive into these stocks without researching tangible data. Therefore, today’s article will discuss seven short-squeeze stocks as well as their fundamental metrics so that interested investors can make better informed decisions. Institutional investors
Mid-cap stocks are often overlooked. However, there are terrific dividend stocks in the mid-cap group that we think are worthy of consideration for income investors. In the world of investing, many investors focus on the biggest stocks in the market – so-called large caps – for their stability and predictability. This makes large-cap stocks generally
Increased concern over inflation and valuations have brought choppiness back to equity markets. As the stock market recovers from a volatile month of trading, investors have turned their attention towards more defensive stocks. For many market participants, dividend shares seem to be the most reasonable plays. High-yield dividend stocks are prized among income investors, as
Most investors who want to gain exposure to the financial sector focus exclusively on the well-known U.S. bank stocks, such as Wells Fargo (NYSE:WFC) and Bank of America (NYSE:BAC), and that goes for income investors as well. However, some Canadian bank stocks have much lower valuations and also have higher dividend yields than their domestic counterparts.
Merck (NYSE:MRK) has been making news lately for research into a possible pill that would treat Covid-19. The coronavirus pill has led to a surge in MRK stock. Source: Atmosphere1 / Shutterstock.com The stock has had a smooth ride over the year and is trading close to the same level as last year. It stood
Bank of America (NYSE:BAC) is worth considerably more than its present price. In fact, my view is that it’s worth somewhere between 15% and 50% more from its Jul. 7 close. That means BAC stock should trade between $45.65 and $59.63 per share. The average between these two is $52.64 per share, or about 32%
They say fools rush in where angels fear to tread, and so it is that I am once again writing about Ocugen (NASDAQ:OCGN) stock. Source: Shutterstock And once again, at the risk of sounding like a fool, I simply don’t understand the bull case for OCGN stock based on a potential Covid-19 vaccine. Ocugen is
If you took a look at the price chart for Penn National Gaming (NASDAQ:PENN), you can’t help but come away with the impression that its shares have traded strangely in line with new novel coronavirus infections. You’ll recall that public health officials recommended people avoid Super Bowl parties due to the threat of dramatically rising
Just 18 months ago, Palantir (NYSE:PLTR) was a struggling tech unicorn. Its revenue growth was decelerating, and its valuation was rumored to be declining on the private market. All the signs pointed to Palantir not living up to its long-running hype. However, PLTR stock came public via a direct listing last fall, and soon the meme-trading
I’ve been a big fan of bank stocks for years. This is mainly due to their humble valuations. All the major ones are of great quality yet have been cheap for far too long. By saying that, a reader would presume that I am writing positively about the upside opportunity in Bank of America (NYSE:BAC)
Any time I write about meme stocks, I like to distinguish between trading and investing. I have no idea where AMC Entertainment (NYSE:AMC) will trade next week or next month. If you are YOLOing on AMC stock the same way you’s bet on a horse at the Kentucky Derby, this story is not for you.
Despite a decline of nearly 10% from June 21 through June 25, MicroVision (NASDAQ:MVIS) remains a Reddit stock winner in 2021. As I write this article, MVIS stock is up over 178% for the year. It’s hard to argue that retail investors haven’t been successful. Their conviction — and short interest that sits around 17%
Given Organon & Co’s (NYSE:OGN) low growth, its sizeable competition, its lack of concrete positive catalysts, and the fact that its management plans to institute an average dividend in the future, I urge investors to avoid OGN stock for now. Source: Shutterstock Moreover, although Organon says that it’s looking to make acquisitions, its relatively low
MindMed (NASDAQ:MNMD) is a neuro-pharmaceutical company that specializes in psychedelic medicine. It discovers, develops and deploys these products to improve health, promote wellness and alleviate suffering. MNMD stock spiked after its initial public offering (IPO) in April, but has cooled since. Source: Shutterstock Is this a buying opportunity, or should investors steer clear of the stock? If
There’s an argument to be made that all of the recent movement in Orphazyme (NASDAQ:ORPH) is simply a sign of the times. Even if it isn’t, there’s little reason to invest in ORPH stock now. That’s because the recent price spikes and subsequent shareholder announcements were little more than bets. Source: Shutterstock Before the spike,
Download Preston’s 1 page checklist for finding great stock picks: http://buffettsbooks.com/checklist Preston Pysh is the #1 selling Amazon author of two books on Warren Buffett. The books can be found at the following location: In this lesson, we began to understand the important terms that truly value a bond. Since most investors will never hold